NA
LAB icon

NewEdge Advisors’s Standard BioTools LAB Stock Holding History

NewEdge Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-300
Closed -$531 – 3882
2024
Q2 		$531 Buy
+300
New +$733 ﹤0.01% 3558
2023
Q2 		– Sell
-169
Closed -$330 – 3573
2023
Q1 		$330 Hold
169
– – ﹤0.01% 3280
2022
Q4 		$0 Buy
+169
New +$208 ﹤0.01% 4158

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's LAB Position: Q3 2024 in Review

NewEdge Advisors sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 300 shares — an estimated $531 sold.

NewEdge Advisors first reported a position in LAB in Q4 2022 and held it in 3 quarters. The position peaked at $531 in Q2 2024. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

  • NewEdge Advisors reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
  • NewEdge Advisors sold 300 Standard BioTools shares in Q3 2024, an estimated $531.
  • NewEdge Advisors first reported a position in Standard BioTools in Q4 2022 and held it in 3 quarters.
  • NewEdge Advisors's Standard BioTools position peaked at $531 in Q2 2024.
  • 141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.